<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Low-molecular weight heparin and dose adjustment in pediatric patients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Low-molecular weight heparin and dose adjustment in pediatric patients</h1>
<div class="graphic"><div class="figure"><div class="ttl">Low-molecular weight heparin and dose adjustment in pediatric patients</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1" colspan="3">Initial dosing for LMWH agents in pediatric patients with normal kidney function*</td> </tr> <tr> <td class="subtitle2">Drug</td> <td class="subtitle2">Therapeutic anticoagulation<br/> (for treatment of thrombosis)</td> <td class="subtitle2">Prophylaxis<br/> (for prevention of thrombosis)</td> </tr> <tr> <td>Enoxaparin</td> <td> <p><strong>Preterm neonates:</strong> 2 mg/kg/dose subQ every 12 hours</p> <p><strong>Term neonates:</strong> 1.5 to 1.7 mg/kg/dose subQ every 12 hours</p> <strong>Infants ≥2 months, children, and adolescents:</strong> 1 mg/kg/dose subQ every 12 hours<sup>¶</sup></td> <td> <p><strong>Infants &lt;2 months:</strong> 0.75 mg/kg/dose subQ every 12 hours</p> <strong>Infants ≥2 months, children, and adolescents:</strong> 0.5 mg/kg/dose subQ every 12 hours</td> </tr> <tr> <td>Dalteparin</td> <td> <p><strong>Neonates:</strong> Limited data available; use of an alternative agent is suggested</p> <p><strong>Infants and children &lt;2 years:</strong> 150 units/kg/dose SubQ every 12 hours</p> <p><strong>Children 2 to &lt;8 years:</strong> 125 units/kg/dose SubQ every 12 hours</p> <strong>Children &gt;8 years and adolescents:</strong> 100 units/kg/dose SubQ every 12 hours (maximum 18,000 units/dose)</td> <td> <p><strong>Neonates:</strong> Limited data available; use of an alternative agent is suggested</p> <p><strong>Infants and children &lt;50 kg:</strong> 100 units/kg/dose SubQ daily (maximum 5000 units/dose)</p> <strong>Children and adolescents ≥50 kg:</strong> 5000 units SubQ daily</td> </tr> <tr> <td>Nadroparin<sup>Δ</sup></td> <td> <p><strong>Neonates:</strong> 150 to 180 units/kg/dose SubQ every 12 hours</p> <strong>Infants, children, and adolescents:</strong> 86 units/kg/dose SubQ every 12 hours (maximum dose 17,100 units/day)</td> <td> <p><strong>Infants and children &lt;50 kg:</strong> Limited data available; use of an alternative agent is suggested</p> <strong>Adolescents ≥50 kg:</strong> 3800 units SubQ once daily</td> </tr> <tr> <td>Reviparin<sup>Δ</sup></td> <td> <p><strong>Infants &lt;5 kg:</strong> 150 units/kg/dose SubQ every 12 hours</p> <strong>Infants and children ≥5 kg:</strong> 100 units/kg/dose SubQ every 12 hours</td> <td> <p><strong>Infants &lt;5 kg:</strong> 50 units/kg/dose SubQ every 12 hours</p> <strong>Infants and children ≥5 kg:</strong> 30 units/kg/dose SubQ every 12 hours</td> </tr> <tr class="divider_bottom"> <td>Tinzaparin<sup>Δ</sup></td> <td> <p><strong>Infants 0 to 2 months:</strong> 275 units/kg/dose SubQ daily</p> <p><strong>Infants 2 to 12 months:</strong> 250 units/kg/dose SubQ daily</p> <p><strong>Children 1 to 5 years:</strong> 240 units/kg/dose SubQ daily</p> <p><strong>Children 5 to 10 years:</strong> 200 units/kg/dose SubQ daily (maximum 18,000 units/dose)</p> <strong>Children and adolescents 10 to 16 years:</strong> 175 units/kg/dose SubQ daily (maximum 18,000 units/dose)</td> <td><strong>Infants and children 1 month to 17 years:</strong> 50 units/kg/dose SubQ daily</td> </tr> <tr> <td class="subtitle1" colspan="3">Dose titration (for therapeutic anticoagulation only)<sup>◊</sup></td> </tr> <tr> <td class="subtitle2">Anti-factor Xa level</td> <td class="subtitle2">Dose titration</td> <td class="subtitle2">Time to repeat anti-factor Xa level</td> </tr> <tr> <td>&lt;0.35 units/mL</td> <td>Increase dose by 25%</td> <td>4 hours after next dose</td> </tr> <tr> <td>0.35 to 0.49 units/mL</td> <td>Increase dose by 10%</td> <td>4 hours after next dose</td> </tr> <tr> <td>0.5 to 1 unit/mL</td> <td>Keep same dose</td> <td> <p>Repeat the next day (4 hours after dose)</p> If stable, can go to weekly monitoring</td> </tr> <tr> <td>1.1 to 1.5 units/mL</td> <td>Decrease dose by 20%</td> <td>Before next dose</td> </tr> <tr> <td>1.6 to 2 units/mL</td> <td>Hold dose for 3 hours, then decrease dose by 30%</td> <td>Before next dose, then 4 hours after next dose</td> </tr> <tr> <td>&gt;2 units/mL</td> <td>Hold all doses until anti-factor Xa is 0.5 units/mL, then decrease dose by 40%</td> <td>Before next dose and every 12 hours until anti-factor Xa is &lt;0.5 units/mL</td> </tr> </tbody></table></div><div class="graphic_footnotes">LMWH: low molecular weight heparin; 
	subQ: subcutaneously.<br/>
	
	* Dose adjustment is necessary for patients with kidney impairment. More frequent monitoring of anti-factor Xa levels may also be warranted. Refer to UpToDate topics on pediatric thrombosis for additional details.<br/>
	
	¶ Some clinicians use slightly higher doses of enoxaparin in infants and young children (eg, for infants ages 3 to 12 months, 1.5 mg/kg/dose SubQ every 12 hours; for children ages 1 to 5 years, 1.2 mg/kg/dose SubQ every 12 hours).<br/>
	
	Δ Nadroparin and tinzaparin are not available in the United States; reviparin is not available in most markets, including the United States.<br/>
<span class="lozenge">◊</span> For <strong>therapeutic anticoagulation</strong>, LMWH is initiated according to the dosing guidance above and the dose is subsequently adjusted as needed to achieve anti-factor Xa levels between 0.5 and 1 units/mL in samples taken 4 to 6 hours after the last dose. The nomogram above has been most well studied in patients receiving enoxaparin; studies on dose titration using other LMWH agents in children are more limited. For <strong>prophylaxis</strong>, monitoring anti-factor Xa levels is generally not necessary; however, monitoring anti-factor Xa levels may be appropriate in select circumstances (eg, patients with kidney impairment). Refer to UpToDate topics on pediatric thrombosis for additional details.</div><div class="graphic_reference">References:
	<ol>
<li>Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.</li>
<li>Malowany JI, Monagle P, Knoppert DC, et al. Enoxaparin for neonatal thrombosis: A call for a higher dose for neonates. Thromb Res 2008; 122:826.</li>
<li>Kuhle S, Massicotte P, Dinyari M, et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005; 94:1164.</li>
<li>Klaassen ILM, Sol JJ, Suijker MH, et al. Are low-molecular-weight heparins safe and effective in children? A systematic review. Blood Rev 2019; 33:33.</li>
<li>Sol J, Boerma M, Klaassen I, et al. Effectiveness and Safety of Nadroparin Therapy in Preterm and Term Neonates with Venous Thromboembolism. J Clin Med 2021; 10:1483.</li>
</ol></div><div id="graphicVersion">Graphic 64075 Version 17.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
